Core Insights - Affimed N.V. presented findings on its innate cell engager (ICE®) AFM24 for advanced non-small cell lung cancer (NSCLC) at the 2025 AACR Annual Meeting, highlighting the potential of AFM24 as a novel immunotherapy treatment [1][5] Exposure-Response Analysis - The analysis involved 72 NSCLC patients treated with either 480 mg of AFM24 monotherapy or in combination with atezolizumab, categorizing patients into high and low exposure groups based on median trough levels [2][4] - A quartile analysis showed a significant increase in objective response rate (ORR) from 0% in the lowest quartile to 50% in the highest quartile, with a notable ORR of 37.04% in the high-exposure group versus 7.14% in the low-exposure group [4][10] - Higher drug exposure was associated with improved outcomes, including a median progression-free survival (mPFS) of 7.3 months in the high-exposure group compared to 2.9 months in the low-exposure group [9][10] Future Development Plans - Pharmacokinetic modeling suggests that a 720 mg weekly dose of AFM24 will achieve target exposure levels by the second week of treatment, which corresponds to the high exposure group in the analysis [6][7] - The company plans to incorporate the 720 mg dose in future studies to optimize clinical benefits and reduce the risk of early disease progression [6][7] Mechanism of Action - AFM24 is a tetravalent, bispecific ICE® that activates the innate immune system by binding to CD16A on immune cells and epidermal growth factor receptors (EGFR) on tumors, facilitating tumor cell killing through antibody-dependent mechanisms [11] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer, with several ICE® molecules in clinical development for various hematologic and solid tumors [12]
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting